Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-05-20

Clinical Trial Update: Targeting IL-17A for Treatment-Resistant Depression [Phase 2]

View source ↗

Summary

Phase 2 trial investigating an IL-17A-targeting therapy for treatment-resistant depression has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2025-05-20